Scinai Immunotherapeutics Ltd. is making a significant change to its American Depositary Shares (ADSs) ratio, which is set to take effect on November 19, 2026. This decision comes as part of the company's strategy to increase its per-ADS trading price and regain compliance with Nasdaq Listing Rule 5550(a)(2), which mandates a minimum bid price of $1.00 per ADS for continued listing on the Nasdaq Capital Market.
Currently, the ratio is one ADS representing 40,000 ordinary shares. The new ratio will change to one ADS representing 160,000 ordinary shares. For holders of the company’s ADSs, this will have the same effect as a one-for-four reverse split of the ADSs. The company’s ADSs are expected to begin trading on an adjusted basis at the opening of trading on November 19, 2026, under the symbol “SCNI.”
No action is required by the holders of the ADSs to affect this change. However, fractional new ADSs will not be issued; instead, fractional entitlements will be aggregated, and the depositary bank will attempt to sell them. The net cash proceeds from this sale will be distributed to the applicable ADS holders.
Scinai Immunotherapeutics, classified under the SIC code 2836 for Biological Products (No Diagnostic Substances), aims to enhance its market position through this strategic move. The company is currently listed on the Nasdaq under the ticker SCNI.
The filing indicates that while this change is intended to help the company comply with listing requirements, there is no assurance that it will successfully regain or maintain compliance with Nasdaq's standards.
As the industry continues to evolve, other companies in the biological products sector may observe Scinai's approach as they navigate similar challenges related to stock price and compliance with exchange requirements.
Details were not available in the SEC filing regarding any further actions or upcoming filings related to this change.
Read Next
ConnectOne Bancorp reveals investor presentation in 8-K
United Natural Foods releases 2026 Impact Report on sustainability
Agah Ramtin Acquires 50,000 Shares of RenovoRx, Inc.
Matson to Present at Stephens Annual Investment Conference
BRF Investments Acquires Additional Shares in Babcock & Wilcox
Franco-Nevada announces formal discussions on Cobre Panamá










